The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma

Table 1 Basic characteristics of breast cancer patients from the study sample

Basic demographic & clinical characteristics	FEC (n = 73)	FEC-T (n = 60)	All regimens (n = 161) ^a
Age range (years)	28-63	27-65	21-65
Disease stage, n (%) metastatic	12 (16)	1 (2)	20 (12)
Bone metastasis, n (%)	7 (10)	0 (0)	12 (7)
HER status, n (%) positive	17 (23)	25 (42)	53 (33)
Prior/concomitant surgery, n (%)	67 (92)	53 (88)	145 (90)
Prior/concomitant radiotherapy, n (%)	49 (67)	40 (67)	111 (69)
Prior/concomitant hormone therapy, n (%)	42 (58)	33 (55)	90 (56)

Basic demographic and clinical characteristics of the breast cancer patients are presented for the two most frequent chemotherapy regimens, and all regimens.
^aOther regimens used in the sample but not displayed were docetaxel (n = 9), AC → T (n = 5), capecitabine/docetaxel (n = 2), capecitabine/docetaxel/trastuzumab (n = 2), docetaxel/trastuzumab (n = 2), epirubicin/cyclophosphamide (n = 2), FEC/trastuzumab (n = 2) and capecitabine/larotaxel, doxorubicin/docetaxel, epirubicin/docetaxel, epirubicin/cyclophosphamide/larotaxel (1 patient each)

ISSN: 1471-2407